Spealman R D
Harvard Medical School, New England Regional Primate Research Center, Southborough, Massachusetts, USA.
J Pharmacol Exp Ther. 1995 Oct;275(1):53-62.
Noradrenergic involvement in the discriminative stimulus (DS) effects of cocaine was investigated in squirrel monkeys by using a two-lever drug discrimination procedure in which responding was maintained by a fixed-ratio schedule of stimulus-shock termination. Monkeys initially were trained to discriminate a relatively high dose of cocaine (1.0 mg/kg i.m.) from saline and subsequently were retrained to discriminate a 3.3- to 5.6-fold lower dose of cocaine (0.30 or 0.18 mg/kg i.m.). The selective norepinephrine[fnc] uptake inhibitors talsupram, tomoxetine, nisoxetine and desipramine substituted for cocaine in the majority of subjects under the low-dose training condition, whereas the selective dopamine uptake inhibitor GBR 12909 [1-(2-[bis(4-fluorophenyl)methoxy]ethyl)-4-(3-phenylpropyl) piperazine] substituted for cocaine under both training conditions and the selective serotonin uptake inhibitor citalopram failed to substitute for cocaine under either condition. Representative alpha-1 [St 587 (2-(2-chloro-5-trifluoromethyl-phenylimino)imidazolidine] and SDZ NVI 085 [(-)-(4aR, 10aR)-3,4,4a,5,10,10a-hexahydro-6-methoxy-4- methyl-4-methyl-9-(methylthio)-2H-naphth[2,3-b]-1,4-oxazine)], alpha-2 (clonidine and UK 14,304 (5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine]) and beta (clenbuterol) adrenoceptor agonists did not consistently substitute for cocaine under either condition in which they were studied. Pretreatment with the alpha-1 adrenoceptor blocker prazosin antagonized the DS effects of cocaine under both training conditions as well as the cocaine-like effects of talsupram and tomoxetine, but not GBR 12909, under the low-dose training condition. Pretreatment with the alpha-2 blocker efaroxan, the nonselective alpha blocker phentolamine and the beta blocker propranolol failed to alter the DS effects of cocaine consistently under either condition in which they were studied. Pretreatment with talsupram, at doses that did not substitute for cocaine when administered alone, enhanced the cocaine-like effects of GBR 12909 under both training conditions. The results support a role for norepinephrine uptake and alpha-1 adrenoceptor mechanisms in the DS effects of cocaine, possibly reflecting a facilitory noradrenergic influence on mesocorticolimbic dopamine activity.
通过使用双杠杆药物辨别程序,在松鼠猴中研究了去甲肾上腺素能系统对可卡因辨别刺激(DS)效应的影响。在该程序中,通过固定比率的刺激 - 电击终止时间表来维持反应。猴子最初接受训练,以区分相对高剂量的可卡因(1.0毫克/千克,肌肉注射)和生理盐水,随后重新训练以区分剂量降低3.3至5.6倍的可卡因(0.30或0.18毫克/千克,肌肉注射)。在低剂量训练条件下,大多数受试者中,选择性去甲肾上腺素[fnc]摄取抑制剂他索普明、托莫西汀、尼索西汀和地昔帕明可替代可卡因,而选择性多巴胺摄取抑制剂GBR 12909 [1-(2-[双(4-氟苯基)甲氧基]乙基)-4-(3-苯基丙基)哌嗪]在两种训练条件下均可替代可卡因,选择性5-羟色胺摄取抑制剂西酞普兰在两种条件下均不能替代可卡因。代表性的α-1 [St 587 (2-(2-氯-5-三氟甲基-苯基亚氨基)咪唑烷)]和SDZ NVI 085 [(-)-(4aR, 10aR)-3,4,4a,5,10,10a-六氢-6-甲氧基-4-甲基-4-甲基-9-(甲硫基)-2H-萘并[2,3-b]-1,4-恶嗪)]、α-2(可乐定和UK 14,304 (5-溴-N-(4,5-二氢-1H-咪唑-2-基)-6-喹喔啉胺))和β(克伦特罗)肾上腺素能受体激动剂在研究的任何条件下均不能始终如一地替代可卡因。在两种训练条件下,用α-1肾上腺素能受体阻滞剂哌唑嗪预处理可拮抗可卡因的DS效应以及他索普明和托莫西汀的可卡因样效应,但在低剂量训练条件下不能拮抗GBR 12909的效应。用α-2阻滞剂依发罗新、非选择性α阻滞剂酚妥拉明和β阻滞剂普萘洛尔预处理,在研究的任何条件下均不能始终如一地改变可卡因的DS效应。单独给药时不能替代可卡因的剂量的他索普明预处理,在两种训练条件下均增强了GBR 12909的可卡因样效应。结果支持去甲肾上腺素摄取和α-1肾上腺素能受体机制在可卡因的DS效应中起作用,这可能反映了去甲肾上腺素能系统对中脑皮质边缘多巴胺活性的促进作用。